Barinthus Biotherapeutics plc (FRA:2AB)
Germany · Delayed Price · Currency is EUR 0.5750
+0.0400 (7.48%)
Last updated: Aug 27, 2026, 8:03 AM CET
Barinthus Biotherapeutics Statistics
Total Valuation
FRA:2AB has a market cap or net worth of EUR 24.77 million. The enterprise value is -17.24 million.
| Market Cap | 24.77M |
| Enterprise Value | -17.24M |
Important Dates
The next estimated earnings date is Friday, November 6, 2026.
| Earnings Date | Nov 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +1.88% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 11.74% |
| Owned by Institutions (%) | 30.89% |
| Float | 27.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.50 |
| P/TBV Ratio | 0.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.54, with a Debt / Equity ratio of 0.18.
| Current Ratio | 5.54 |
| Quick Ratio | 5.33 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.39 |
| Interest Coverage | -606.23 |
Financial Efficiency
Return on equity (ROE) is -52.38% and return on invested capital (ROIC) is -22.08%.
| Return on Equity (ROE) | -52.38% |
| Return on Assets (ROA) | -18.99% |
| Return on Invested Capital (ROIC) | -22.08% |
| Return on Capital Employed (ROCE) | -45.59% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -2.61M |
| Employee Count | 14 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -146,175 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.03% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -41.03% |
| 50-Day Moving Average | 0.51 |
| 200-Day Moving Average | 0.54 |
| Relative Strength Index (RSI) | 62.50 |
| Average Volume (20 Days) | 60 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.12 |
Income Statement
| Revenue | n/a |
| Gross Profit | 7.52M |
| Operating Income | -28.12M |
| Pretax Income | -36.74M |
| Net Income | -36.56M |
| EBITDA | -27.35M |
| EBIT | -28.12M |
| Earnings Per Share (EPS) | -0.90 |
Balance Sheet
The company has 51.90 million in cash and 9.01 million in debt, with a net cash position of 42.89 million.
| Cash & Cash Equivalents | 51.90M |
| Total Debt | 9.01M |
| Net Cash | 42.89M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 50.01M |
| Book Value Per Share | 1.22 |
| Working Capital | 45.38M |
Cash Flow
| Operating Cash Flow | -23.13M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 760,153 |
| Net Borrowing | n/a |
| Free Cash Flow | -23.13M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:2AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.88% |
| Shareholder Yield | -1.88% |
| Earnings Yield | -147.61% |
| FCF Yield | -93.39% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |